Page 54 - Read Online

Page 61 Ryan et al. J Transl Genet Genom. 2025;9:48-61 https://dx.doi.org/10.20517/jtgg.2024.87

5. Braun F, Abed A, Sellung D, et al. Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy. J Clin Invest.
2023;133:e157782. DOI
6. Talbot A, Nicholls K, Fletcher JM, Fuller M. A simple method for quantification of plasma globotriaosylsphingosine: utility for Fabry
disease. Mol Genet Metab. 2017;122:121-5. DOI
7. Santostefano M, Cappuccilli M, Gibertoni D, et al. Fabry disease nephropathy: histological changes with nonclassical mutations and
genetic variants of unknown significance. Am J Kidney Dis. 2023;82:581-96.e0. DOI
8. Maruyama H, Miyata K, Mikame M, et al. Effectiveness of plasma lyso-Gb as a biomarker for selecting high-risk patients with Fabry
3
disease from multispecialty clinics for genetic analysis. Genet Med. 2019;21:44-52. DOI PubMed PMC
9. Liebau MC, Braun F, Höpker K, et al. Dysregulated autophagy contributes to podocyte damage in Fabry's disease. PLoS One.
2013;8:e63506. DOI PubMed PMC
10. Wise AF, Krisnadevi IA, Bruell S, et al. Fabry disease podocytes reveal ferroptosis as a potential regulator of cell pathology. Kidney
Int Rep. 2025;10:535-48. DOI PMC
11. Kim SY, Park S, Lee SW, et al. RIPK3 contributes to Lyso-Gb3-induced podocyte death. Cells. 2021;10:245. DOI
12. Najafian B, Tøndel C, Svarstad E, Gubler MC, Oliveira JP, Mauer M. Accumulation of globotriaosylceramide in podocytes in Fabry
nephropathy is associated with progressive podocyte loss. J Am Soc Nephrol. 2020;31:865-75. DOI PubMed PMC
13. Tebani A, Barbey F, Dormond O, et al. Deep next-generation proteomics and network analysis reveal systemic and tissue-specific
patterns in Fabry disease. Transl Res. 2023;258:47-59. DOI
14. Tebani A, Mauhin W, Abily-Donval L, et al. A proteomics-based analysis reveals predictive biological patterns in Fabry disease. J
Clin Med. 2020;9:1325. DOI
15. Ter Huurne M, Parker BL, Liu NQ, et al. GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from
Fabry-affected individuals. Am J Hum Genet. 2023;110:1600-5. DOI
16. Wise AF, Saini S, Ricardo SD. The differentiation of human induced pluripotent stem cells into podocytes in vitro. Methods Mol Biol.
2022;2454:317-25. DOI PubMed
17. Song B, Smink AM, Jones CV, et al. The directed differentiation of human iPS cells into kidney podocytes. PLoS One. 2012;7:e46453.
DOI PubMed PMC
18. Lau RWK, Fisher C, Phan TK, et al. Modelling X-linked alport syndrome with induced pluripotent stem cell-derived podocytes.
Kidney Int Rep. 2021;6:2912-7. DOI PubMed PMC
19. Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA.
2008;105:2812-7. DOI PubMed PMC
20. Taguchi A, Ishii S, Mikame M, Maruyama H. Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a
mouse model of classic Fabry disease. Mol Genet Metab Rep. 2023;34:100952. DOI PubMed PMC
21. Elsaid HOA, Rivedal M, Skandalou E, et al. Proteomic analysis unveils Gb3-independent alterations and mitochondrial dysfunction in
-/-
a gla zebrafish model of Fabry disease. J Transl Med. 2023;21:591. DOI PubMed PMC
22. Sanchez-Niño MD, Carpio D, Sanz AB, Ruiz-Ortega M, Mezzano S, Ortiz A. Lyso-Gb3 activates Notch1 in human podocytes. Hum
Mol Genet. 2015;24:5720-32. DOI
23. Beck M, Ramaswami U, Hernberg-Ståhl E, et al. Twenty years of the Fabry outcome survey (FOS): insights, achievements, and
lessons learned from a global patient registry. Orphanet J Rare Dis. 2022;17:238. DOI PubMed PMC
24. Moore DF, Krokhin OV, Beavis RC, et al. Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify
biological abnormalities. Proc Natl Acad Sci USA. 2007;104:2873-8. DOI
25. Chimenti C, Hamdani N, Boontje NM, et al. Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease. Am
J Pathol. 2008;172:1482-90. DOI
26. Birket MJ, Raibaud S, Lettieri M, et al. A human stem cell model of Fabry disease implicates LIMP-2 accumulation in cardiomyocyte
pathology. Stem Cell Rep. 2019;13:380-93. DOI PubMed PMC
27. Deegan PB, Goker-Alpan O, Geberhiwot T, et al. Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment
over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study. Mol Genet Metab.
2023;138:106963. DOI PubMed PMC
28. Guérard N, Oder D, Nordbeck P, et al. Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and
pharmacokinetics in patients with Fabry disease on enzyme replacement. Clin Pharmacol Ther. 2018;103:703-11. DOI